The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels

F RANK M. S ACKS , M.D., M ARC A. P FEFFER , M.D., P H .D., L EMUEL A. M OYE , M.D., P H .D., J EAN L. R OULEAU , M.D., J OHN D. R UTHERFORD , M.D., T HOMAS G. C OLE , P H .D., L ISA B ROWN , M.P.H., J. W AYNE W ARNICA , M.D., J. M ALCOLM O. A RNOLD , M.D., C HUAN -C HUAN W UN , P H .D., B ARRY R. D AVIS , M.D., P H .D., AND E UGENE B RAUNWALD , M.D., FOR THE C HOLESTEROL AND R ECURRENT E VENTS T RIAL I NVESTIGATORS *

[1]  J. Massé.  Effect of lovastatin on early carotid atherosclerosis. , 1995, Circulation.

[2]  B. Rosner,et al.  The influence of pretreatment lew density lipoprotein cholesterol concentrations on the effect of hypocholesterolemic therapy on coronary atherosclerosis in angiographic trials , 1995 .

[3]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[4]  C. Furberg,et al.  Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II) , 1995, The American journal of cardiology.

[5]  J. Salonen,et al.  Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. , 1995, Circulation.

[6]  K. Anderson,et al.  Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease. , 1992, Journal of the American College of Cardiology.

[7]  Ames,et al.  PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA , 2000 .

[8]  L. Kuller,et al.  SERUM CHOLESTEROL, BLOOD PRESSURE, AND MORTALITY: IMPLICATIONS FROM A COHORT OF 361 662 MEN , 1986, The Lancet.

[9]  P. Renshaw,et al.  [Detection, evaluation, and treatment of high blood cholesterol in adults]. , 2001, Revista panamericana de salud publica = Pan American journal of public health.

[10]  C. Lavie,et al.  National Cholesterol Education Program's recommendations, and implications of "missing" high-density lipoprotein cholesterol in cardiac rehabilitation programs. , 1991, The American journal of cardiology.

[11]  B. Rosner,et al.  Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients , 1994, The Lancet.

[12]  W. Kannel.  Range of serum cholesterol values in the population developing coronary artery disease. , 1995, The American journal of cardiology.

[13]  C. Furberg,et al.  Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. , 1995, Circulation.

[14]  D. Illingworth.  Carcinogenicity of lipid-lowering drugs. , 1996, JAMA.

[15]  I. Holme.  Cholesterol reduction and its impact on coronary artery disease and total mortality. , 1995, The American journal of cardiology.

[16]  J Pekkanen,et al.  Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. , 1990, The New England journal of medicine.

[17]  A. Dobs,et al.  Long-term endocrine function in hypercholesterolemic patients treated with pravastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. , 1993, Metabolism: clinical and experimental.

[18]  D. Gordon,et al.  Declining serum total cholesterol levels among US adults. The National Health and Nutrition Examination Surveys. , 1993, JAMA.

[19]  T. Wilt,et al.  Distribution of lipids in 8,500 men with coronary artery disease. Department of Veterans Affairs HDL Intervention Trial Study Group. , 1995, The American journal of cardiology.

[20]  C. Furberg,et al.  Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. , 1994, Circulation.

[21]  J. Buring,et al.  Decreased HDL2 and HDL3 Cholesterol, Apo A‐I and Apo A‐II, and Increased Risk of Myocardial Infarction , 1992, Circulation.

[22]  J. Mckenney,et al.  Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) , 1993, JAMA.

[23]  M. Pfeffer,et al.  Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events trial (CARE) , 1991, The American journal of cardiology.

[24]  J. Rossouw.  Lipid-lowering interventions in angiographic trials. , 1995, The American journal of cardiology.

[25]  D.,et al.  Regression Models and Life-Tables , 2022 .

[26]  U. Tomiyasu,et al.  A Controlled Clinical Trial of a Diet High in Unsaturated Fat in Preventing Complications of Atherosclerosis , 1969 .